NCT06622304Completed
Exploring the Effects of Antihypertensive and Lipid-Lowering Drugs on Inflammatory Cytokine Levels
Mendelian Randomization Analysis of Drug Targets: Exploring the Impact of Antihypertensive and Lipid-Lowering Therapies on Inflammatory Cytokines
Source: ClinicalTrials.gov · Last updated 3 Oct 2024
Brief summary (registry, in English)
This study investigates the causal relationships between antihypertensive and lipid-lowering drugs and inflammatory cytokines using a drug-targeted Mendelian randomization approach. By leveraging genome-wide association studies (GWAS) and expression quantitative trait loci (eQTL) data, the study evaluates the effects of angiotensin-converting enzyme inhibitors (ACEIs), angiotensin receptor blockers (ARBs), HMG-CoA reductase inhibitors, PCSK9 inhibitors, and NPC1L1 inhibitors on key inflammatory cytokines such as IL-1β, TNF-α, CRP, and MCP-1. The findings aim to provide insights into the prevention and control of excessive inflammatory responses, particularly in patients with hypertension and dyslipidemia, by assessing the causal effects of these therapies.
- Status (registry)
- Completed
- Study type
- Observational
- Enrollment
- 250736 (actual)
- First submitted
- 29 Sept 2024
- Start date
- 1 Apr 2024
- Primary completion date
- 1 Aug 2024
- Lead sponsor
- Guangzhou Institute of Respiratory Disease
- Diseases
- High blood pressure
- NCT number
- NCT06622304
What you commit to
- Study type: Observational
- Participants enrolled: 250736
- From 1 Apr 2024 to the primary completion date, 1 Aug 2024
- 1 site in 1 country
- Visits and tests: ask the trial team, the registry does not list them
Built from the registry fields of ClinicalTrials.gov. It describes the study, not your situation.
Who cannot take part
Copied verbatim from ClinicalTrials.gov and grouped by topic. Only the trial team decides who can take part.
Other illness
- Individuals with severe chronic diseases or other conditions that may significantly influence inflammatory responses.
Age
- Participants under the age of 18.
Other
- Individuals unwilling or unable to provide necessary clinical or genomic data.
- Pregnant or breastfeeding women.
Who the study is looking for
- Participants aged 18 years or older.
- Diagnosed with hypertension, coronary artery disease, or dyslipidemia.
- Availability of complete genome-wide data and inflammatory cytokine levels.
- Willingness to participate in the study and provide the required clinical data.
Age in the registry: 18 years to - · Sex: All · Does not accept healthy volunteers
Sites (1)
Sites in registry order. Pick your city on the disease page to sort them by distance.
| Site | City | Country | Site status |
|---|---|---|---|
| Guangzhou Institute of Respiratory Diseases, the First Affiliated Hospital of Guangzhou Medical University Coordinator of this site? Confirm its status | Guangzhou | China | Unknown status |
This page is information, not medical advice. Discuss any trial with your doctor.